Trial Profile
A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Brain tumour initiating cell vaccine (Primary) ; Imiquimod (Primary)
- Indications Astrocytoma; Glioma
- Focus Adverse reactions; Pharmacodynamics
- 20 Feb 2020 Status changed from active, no longer recruiting to completed.
- 21 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2019.
- 21 Nov 2017 Planned primary completion date changed from 1 Sep 2015 to 1 Dec 2017.